A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
Price : $35 *
At a glance
- Drugs Telbermin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Newron Sweden AB
- 26 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 05 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 28 Oct 2014 New trial record